$VKTX
Viking Therapeutics, Inc. Stock $vktx

$vktx Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-K Financial Statement

#000156459016014212 Filed on March 08, 2016

Income Statement

Concept	2015 Q4	2015	2014 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.400M	$5.030M	$210.0K
YoY Change	566.67%	305.65%
% of Gross Profit
Research & Development	$3.220M	$6.967M	$140.0K
YoY Change	2200.0%	-68.65%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$4.620M	$12.00M	$350.0K
YoY Change	1220.0%	-48.88%
Operating Profit		-$12.00M
YoY Change		-48.88%
Interest Expense	-$250.0K	-$88.68K	-$330.0K
YoY Change	-24.24%	-85.92%
% of Operating Profit
Other Income/Expense, Net	-$220.0K	-$10.43M	$2.080M
YoY Change	-110.58%	-571.95%
Pretax Income	-$5.090M	-$23.40M	$1.390M
YoY Change	-466.19%	6.95%
Income Tax
% Of Pretax Income
Net Earnings	-$5.090M	-$23.40M	$1.390M
YoY Change	-466.19%	6.97%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.014M	-$3.679M	$157.2K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.10M	$14.10M	$800.0K
YoY Change	1662.5%	1662.5%	300.0%
Cash & Equivalents	$768.6K		$755.9K
Short-Term Investments	$13.30M	$13.30M
Other Short-Term Assets	$1.100M	$1.100M	$0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$15.20M	$15.20M	$773.7K
YoY Change	1864.84%	1800.0%	286.84%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.0K	$200.0K	$775.00
YoY Change	25706.45%	-91.3%
Total Long-Term Assets	$237.5K	$200.0K	$2.269M
YoY Change	-89.54%	-90.91%
TOTAL ASSETS
Total Short-Term Assets	$15.20M	$15.20M	$773.7K
Total Long-Term Assets	$237.5K	$200.0K	$2.269M
Total Assets	$15.44M	$15.40M	$3.043M
YoY Change	407.34%	413.33%	1421.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$592.4K	$600.0K	$1.831M
YoY Change	-67.64%	-66.67%	1730.72%
Accrued Expenses	$1.400M	$1.400M	$20.30M
YoY Change	-93.1%	-93.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$300.0K
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$1.977M	$2.000M	$22.52M
YoY Change	-91.22%	-91.11%	22417.08%
LONG-TERM LIABILITIES
Long-Term Debt	$2.200M	$2.200M	$1.300M
YoY Change	69.23%	69.23%	550.0%
Other Long-Term Liabilities	$2.600M	$2.600M	$1.400M
YoY Change	85.71%	85.71%	1300.0%
Total Long-Term Liabilities	$4.737M	$4.800M	$2.655M
YoY Change	78.46%	77.78%	784.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.977M	$2.000M	$22.52M
Total Long-Term Liabilities	$4.737M	$4.800M	$2.655M
Total Liabilities	$6.714M	$6.700M	$25.17M
YoY Change	-73.33%	-73.41%	6192.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$45.55M		-$22.14M
YoY Change	105.7%
Common Stock	$54.28M		$12.93K
YoY Change	419811.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.725M	$8.700M	-$22.13M
YoY Change
Total Liabilities & Shareholders Equity	$15.44M	$15.40M	$3.043M
YoY Change	407.34%	413.33%	1421.57%

Cashflow Statement

Concept	2015 Q4	2015	2014 Q4
OPERATING ACTIVITIES
Net Income	-$5.090M	-$23.40M	$1.390M
YoY Change	-466.19%	6.97%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$3.300M	-$8.730M	-$440.0K
YoY Change	650.0%	449.06%	528.57%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$1.960M	-$13.47M
YoY Change
Cash From Investing Activities	$1.960M	-$13.47M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$25.39M
YoY Change		-1269623200.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-30.00K	22.21M	400.0K
YoY Change	-107.5%	923.5%	900.0%
NET CHANGE
Cash From Operating Activities	-3.300M	-8.730M	-440.0K
Cash From Investing Activities	1.960M	-13.47M
Cash From Financing Activities	-30.00K	22.21M	400.0K
Net Change In Cash	-1.370M	10.00K	-40.00K
YoY Change	3325.0%	-98.28%	33.33%
FREE CASH FLOW
Cash From Operating Activities	-$3.300M	-$8.730M	-$440.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2014Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	304274
CY2014Q4	vktx	Debt Conversion Feature Liability Current DebtConversionFeatureLiabilityCurrent	58742
CY2015Q4	us-gaap	Assets Assets	15439103
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	592414
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	80000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17827
CY2014Q4	us-gaap	Assets Current AssetsCurrent	773684
CY2015Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	157455
CY2014Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	2268675
CY2014Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	775
CY2014Q4	us-gaap	Assets Assets	3043134
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1830724
CY2014Q4	vktx	Accrued License Fees Current AccruedLicenseFeesCurrent	19865863
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1384398
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	77222
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1976812
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22517082
CY2015Q4	vktx	Accrued Interest Non Current AccruedInterestNonCurrent	183611
CY2015Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2151540
CY2014Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1264114
CY2015Q4	vktx	Debt Conversion Feature Liability Noncurrent DebtConversionFeatureLiabilityNoncurrent	2370903
CY2014Q4	vktx	Debt Conversion Feature Liability Noncurrent DebtConversionFeatureLiabilityNoncurrent	1390469
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	31239
CY2015Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4737293
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2654583
CY2015Q4	us-gaap	Liabilities Liabilities	6714105
CY2014Q4	us-gaap	Liabilities Liabilities	25171665
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	97
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	60
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	54277716
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	12866
CY2015Q4	vktx	Convertible Notes Payable Discount Noncurrent ConvertibleNotesPayableDiscountNoncurrent	348460
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	2601448
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45545445
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22141457
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7370
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-22128531
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3043134
CY2014Q4	vktx	Convertible Notes Payable Discount Current ConvertibleNotesPayableDiscountCurrent	6076
CY2014Q4	vktx	Convertible Notes Payable Discount Noncurrent ConvertibleNotesPayableDiscountNoncurrent	1235886
CY2015	us-gaap	Revenues Revenues	0
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22223073
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9683741
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9683741
CY2015	us-gaap	Operating Expenses OperatingExpenses	11996478
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-11996478
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6000000
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6000000
CY2014	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2
CY2015	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-79225
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	219237
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	191008
CY2014	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-712
CY2014	us-gaap	Revenues Revenues	0
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6966842
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5029636
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1244910
CY2014	us-gaap	Operating Expenses OperatingExpenses	23467983
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-23467983
CY2015	vktx	Change In Fair Value Of Accrued License Fees ChangeInFairValueOfAccruedLicenseFees	-9381848
CY2014	vktx	Change In Fair Value Of Accrued License Fees ChangeInFairValueOfAccruedLicenseFees	1821713
CY2014	vktx	Change In Fair Value Of Debt Conversion Features ChangeInFairValueOfDebtConversionFeatures	390763
CY2015	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-88682
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23411358
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	3760
CY2014	vktx	Forgiveness Of Note Receivable In Consideration Of Services Rendered ForgivenessOfNoteReceivableInConsiderationOfServicesRendered	2498
CY2015	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	38
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	2205676
CY2015	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	28760
CY2015	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	456412
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	29247711
CY2015	vktx	Issuance Of Common Stock In Initial Public Offering Issuance Costs IssuanceOfCommonStockInInitialPublicOfferingIssuanceCosts	22326366
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8724998
CY2015	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	131899
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	6258
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1079772
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17827
CY2014	vktx	Increase Decrease In Accrued License Fees IncreaseDecreaseInAccruedLicenseFees	21687576
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1560079
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	80972
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8731494
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1591423
CY2015	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	16033042
CY2015	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2563000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-13470042
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25392500
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	332337
CY2015	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	38
CY2014	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2
CY2014	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2500000
CY2015	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	22641
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2167661
CY2015	vktx	Stock Issued In Lieu Of License Fee Payment StockIssuedInLieuOfLicenseFeePayment	29247711
CY2015Q4	vktx	Unpaid Deferred Initial Public Offering Costs UnpaidDeferredInitialPublicOfferingCosts	108791
CY2014Q4	vktx	Unpaid Deferred Initial Public Offering Costs UnpaidDeferredInitialPublicOfferingCosts	1936338
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	456412
CY2015	vktx	Issuance Of Common Stock To Consultant IssuanceOfCommonStockToConsultant	28760
CY2014	vktx	Non Cash Repurchase Of Common Stock NonCashRepurchaseOfCommonStock	1998
CY2015Q2	vktx	Accrued License Fees Current AccruedLicenseFeesCurrent	29247711
CY2014Q4	vktx	Convertible Notes Payable Noncurrent Portion Including Discount ConvertibleNotesPayableNoncurrentPortionIncludingDiscount	2500000
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to determining the fair value of the debt conversion liability and accounting for certain commitments. Actual results could differ from those estimates.</p></div>
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p></div>
CY2015Q2	vktx	Incremental Charge IncrementalCharge	9381848
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3655964
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	29247711
CY2014Q4	vktx	Convertible Notes Payable Current Portion Including Discount ConvertibleNotesPayableCurrentPortionIncludingDiscount	310350
CY2015Q4	vktx	Convertible Notes Payable Noncurrent Portion Including Discount ConvertibleNotesPayableNoncurrentPortionIncludingDiscount	2500000
CY2014Q4	vktx	Reduce The License Fee Liability ReduceTheLicenseFeeLiability	19865863
CY2015	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	8514155
CY2014	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	5860274
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1862509
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2714487
CY2015	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	0
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	0
CY2015	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	13342869
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7370
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	13335499
CY2015Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	14
CY2015Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	13884371
CY2015Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	2370903
CY2014Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	21315074
CY2015	vktx	License Agreement Entered Date LicenseAgreementEnteredDate	2014-05
CY2015	vktx	Date Of Registration Rights Agreement Amendment DateOfRegistrationRightsAgreementAmendment	2016-01-22
CY2015	vktx	License Agreement Date Of Agreement LicenseAgreementDateOfAgreement	2014-12-31
CY2015	vktx	License Agreement Date Of Maturity LicenseAgreementDateOfMaturity	2015-05-04
CY2014Q2	vktx	Accrued License Fees Current AccruedLicenseFeesCurrent	21169616
CY2014Q3	vktx	Incremental Charge IncrementalCharge	517960
CY2014	vktx	Increase Decrease In License Fee Liability And Other Expense IncreaseDecreaseInLicenseFeeLiabilityAndOtherExpense	1821713
CY2015	vktx	Debt Instrument Current Maturities Due Date DebtInstrumentCurrentMaturitiesDueDate	2015
CY2014	vktx	Debt Instrument Current Maturities Due Date DebtInstrumentCurrentMaturitiesDueDate	2015
CY2015Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.05
CY2014Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.05
CY2015	vktx	Debt Instrument Long Term Maturities Due Date DebtInstrumentLongTermMaturitiesDueDate	2016
CY2014	vktx	Debt Instrument Long Term Maturities Due Date DebtInstrumentLongTermMaturitiesDueDate	2016
CY2015Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	310350
CY2015Q2	vktx	Accrued Interest Converted AccruedInterestConverted	24276
CY2015Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	57046
CY2014Q1	us-gaap	Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance	1000000
CY2014Q1	us-gaap	Deferred Compensation Arrangement With Individual Exercise Price DeferredCompensationArrangementWithIndividualExercisePrice	0.01
CY2014Q1	vktx	Number Of Tranches NumberOfTranches	2
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	168000
CY2015Q2	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	633810
CY2015Q2	vktx	Shares Repurchase Price Per Share SharesRepurchasePricePerShare	0.00001
CY2015Q2	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	366190
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	61566
CY2014Q2	vktx	Employment Agreement With Number Of Employees EmploymentAgreementWithNumberOfEmployees	5
CY2015	vktx	Employee Agreement Description EmployeeAgreementDescription	In exchange for this agreement to receive a lower salary, the Company agreed to issue, on the date of the closing of the IPO, to each of these employees a certain amount of fully vested restricted stock equal to the quotient of (1) the product of 150% of the difference between the employee’s post-IPO salary and his or her pre-IPO salary multiplied by the number of days between the date of the closing of the IPO and the date of execution of the employee’s employment agreement, divided by (2) the product of 365 multiplied by the closing sales price of the Company’s common stock on the date of the closing of the IPO.
CY2014Q2	vktx	Percentage Of Salary Difference Between Post And Pre Ipo Quotient Of Product PercentageOfSalaryDifferenceBetweenPostAndPreIPOQuotientOfProduct	1.50
CY2014Q4	vktx	Potential Full Vested Restricted Stock Amount Not Recorded As Liability PotentialFullVestedRestrictedStockAmountNotRecordedAsLiability	520476
CY2015	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	5711
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2601448
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6258
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	443894
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	78500
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	365394
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	40250
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.49
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.54
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.49
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y4M21D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y4M6D
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.26
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.852
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y5M27D
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0181
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2015Q4	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2015Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2420795
CY2014Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	695733
CY2015Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.00
CY2015	vktx	Description Of Warrant DescriptionOfWarrant	The warrant is exercisable for cash or on a cashless basis at a per share exercise price equal to $10.00 commencing on April 28, 2016, one year following the date of the prospectus filed with the SEC relating to the IPO, and expiring on April 28, 2020. In addition, the warrant provides for registration rights upon request, under certain circumstances. The piggyback registration right provided in connection with the warrant will terminate on April 28, 2022
CY2015	vktx	Warrant Expiration Date WarrantExpirationDate	2022-04-28
CY2014Q4	vktx	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	144756
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	5890000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	6629000
CY2015	vktx	Federal And State Net Operating Loss Carryforwards Begin To Expiration Year FederalAndStateNetOperatingLossCarryforwardsBeginToExpirationYear	2032
CY2015	vktx	Initial Public Offering Expiration Date InitialPublicOfferingExpirationDate	2020-04-28
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.08
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.08
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.02
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.01
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.40
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.41
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	48982
CY2015Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	14009497
CY2014Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	7993293
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2430249
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	548247
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	986534
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6306
CY2015Q4	vktx	Deferred Tax Assets Share Conversion Feature DeferredTaxAssetsShareConversionFeature	243759
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3510
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	530
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17722531
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8548376
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17722531
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8403620
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	144756
CY2015	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	Specifically, this limitation may arise in the event of an “ownership change,” which is defined by Section 382 of the Code as a cumulative change in ownership of the Company of more than 50% within a three-year period. If the Company undergoes one or more ownership changes in connection with any future transactions in its stock, the Company’s ability to utilize net operating loss carryforwards to offset federal taxable income, if any, could potentially result in increased future tax liability to the Company. An ownership change under Section 382 of the Code occurred during the year ended December 31, 2015 in connection with the Company’s initial public offering. A portion of the net operating loss carryforwards are subject to an annual limitation.
CY2015	vktx	Percentage Of Cumulative Change In Stock Ownership PercentageOfCumulativeChangeInStockOwnership	0.50
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2015Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	0
CY2014Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	0
CY2015Q3	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	19737
CY2015Q3	vktx	Percentage Of Rent Increases PercentageOfRentIncreases	0.030
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	142288
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	186774
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	180004
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	247611
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	190337
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	617952

Files In Submission

Name	View Source	Status
0001564590-16-014212-index-headers.html	Edgar Link	pending
0001564590-16-014212-index.html	Edgar Link	pending
0001564590-16-014212.txt	Edgar Link	pending
0001564590-16-014212-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g201603081912259284921.jpg	Edgar Link	pending
g201603081912266314922.jpg	Edgar Link	pending
g201603081912266474923.jpg	Edgar Link	pending
g201603081912266634924.jpg	Edgar Link	pending
g201603081912266784925.jpg	Edgar Link	pending
g201603081912270694926.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vktx-10k_20151231.htm	Edgar Link	pending
vktx-20151231.xml	Edgar Link	completed
vktx-20151231.xsd	Edgar Link	pending
vktx-20151231_cal.xml	Edgar Link	unprocessable
vktx-20151231_def.xml	Edgar Link	unprocessable
vktx-20151231_lab.xml	Edgar Link	unprocessable
vktx-20151231_pre.xml	Edgar Link	unprocessable
vktx-ex231_11.htm	Edgar Link	pending
vktx-ex311_10.htm	Edgar Link	pending
vktx-ex312_8.htm	Edgar Link	pending
vktx-ex321_9.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VKTX
Viking Therapeutics, Inc. Stock $vktx

2015 Q4 Form 10-K Financial Statement

#000156459016014212 Filed on March 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VKTX Viking Therapeutics, Inc. Stock $vktx

2015 Q4 Form 10-K Financial Statement

#000156459016014212 Filed on March 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VKTX
Viking Therapeutics, Inc. Stock $vktx